Degradation of apolipoprotein B-100 by lysosomal cysteine cathepsins

Biological Chemistry

Volumn 387, Issue 9, 2006, Pages 1295-1303

  Linke, Martin ^a   Gordon, Ronald E ^b   Brillard, Michèle ^c   Lecaille, Fabien ^c   Lalmanach, Gilles ^c   Brömme, Dieter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MOUNT SINAI HOSPITAL   (United States)

^c INSERM   (France)

Author keywords

Apolipoprotein B 100; Cell associated proteolysis; Cleavage sites; Cysteine cathepsins; LDL particle fusion; N terminal sequencing

Indexed keywords

APOLIPOPROTEIN B100; CATHEPSIN; CATHEPSIN B; CATHEPSIN F; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CATHEPSIN V; CYSTEINE PROTEINASE; LOW DENSITY LIPOPROTEIN; LYSOSOME ENZYME; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CATALYSIS; CELL PH; CHEMICAL MODIFICATION; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FUNCTIONAL PROTEOMICS; GEL ELECTROPHORESIS; INCUBATION TIME; LIPID DEGRADATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING;

AMINO ACID SEQUENCE; APOLIPOPROTEIN B-100; CATHEPSINS; ELECTROPHORESIS; ENZYME ACTIVATION; GELS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOPROTEINS, LDL; LYSOSOMES; MICROSCOPY, ELECTRON; MOLECULAR SEQUENCE DATA; SUBSTRATE SPECIFICITY;

EID: 33748752235     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.160     Document Type: Article

References (49)

1. Alves, M.F., Puzer, L., Cotrin, S.S., Juliano, M.A., Juliano, L., Bromme, D., and Carmona, A.K. (2003). S3 to S3′ subsite specificity of recombinant human Cat K and development of selective internally quenched fluorescent substrates. Biochem. J. 373, 981-986.
2. Andrews, N.W. (2000). Regulated secretion of conventional lysosomes. Trends Cell. Biol. 10, 316-321.
3. Babaev, V.R., Bobryshev, Y.V., Sukhova, G.K., and Kasantseva, I.A. (1993). Monocyte/macrophage accumulation and smooth muscle cell phenotypes in early atherosclerotic lesions of human aorta. Atherosclerosis 100, 237-248.
4. Berger, A. and Schechter, I. (1970). Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 257, 249-264.
5. Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
6. Brömme, D. (2004). Cathepsin F. In: Handbook of Proteolytic Enzymes, 2nd edition, A.J. Barrett, N.D. Rawlings and J.F. Woessner, eds. (Amsterdam, The Netherlands: Elsevier Academic Press), pp. 1087-1088.
7. Bromme, D., Li, Z., Barnes, M., and Mehler, E. (1999). Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry 38, 2377-2385.
8. Cardin, A.D., Witt, K.R., Chao, J., Margolius, H.S., Donaldson, V.H., and Jackson, R.L. (1984). Degradation of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins. J. Biol. Chem. 259, 8522-8528.
9. Chen, G.C., Lau, K., Hamilton, R.L., and Kane, J.P. (1991). Differences in local conformation in human apolipoprotein B-100 of plasma low density and very low density lipoproteins as identified by cathepsin D. J. Biol. Chem. 266, 12581-12587.
10. Cheng, X.W., Kuzuya, M., Nakamura, K., Di, Q., Liu, Z., Sasaki, T., Kanda, S., Jin, H., Shi, G.P., Murohara, T., Yokota, M., and Iguchi, A. (2006). Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin ανβ3. Am. J. Pathol. 168, 685-694.
11. Cotrin, S.S., Puzer, L., de Souza Judice, W.A., Juliano, L., Carmona, A.K., and Juliano, M.A. (2004). Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxy-dipeptidases: assays with human cathepsin B. Anal. Biochem. 335, 244-252.
12. De Graaf, J., Hak-Lemmers, H.L., Hectors, M.P., Demacker, P.N., Hendriks, J.C., and Stalenhoef, A.F. (1991). Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11, 298-306.
13. Fukuchi, M., Watanabe, J., Kumagai, K., Baba, S., Shinozaki, T., Miura, M., Kagaya, Y., and Shirato, K. (2002). Normal and oxidized low density lipoproteins accumulate deep in physiologically thickened intima of human coronary arteries. Lab. Invest. 82, 1437-1447.
14. Garcia-Touchard, A., Henry, T.D., Sangiorgi, G., Spagnoli, L.G., Mauriello, A., Conover, C., and Schwartz, R.S. (2005). Extra-cellular proteases in atherosclerosis and restenosis. Arterioscler. Thromb. Vasc. Biol. 25, 1119-1127.
15. + T lymphocytes induce polarized exocytosis of secretory lysosomes by dendritic cells with release of interleukin-1β and cathepsin D. Blood 98, 2152-2159.
16. Hakala, J.K., Oksjoki, R., Laine, P., Du, H., Grabowski, G.A., Kovanen, P.T., and Pentikainen, M.O. (2003). Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 23, 1430-1436.
17. Han, S.R., Momeni, A., Strach, K., Suriyaphol, P., Fenske, D., Paprotka, K., Hashimoto, S.I., Torzewski, M., Bhakdi, S., and Husmann, M. (2003). Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 23, 661-667.
18. Hoff, H.F., Zyromski, N., Armstrong, D., and O'Neil, J. (1993). Aggregation as well as chemical modification of LDL during oxidation is responsible for poor processing in macrophages. J. Lipid Res. 34, 1919-1929.
19. Karpe, F. and Hamsten, A. (1994). Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J. Lipid Res. 35, 1311-1317.
20. Kruth, H.S. and Shekhonin, B. (1994). Evidence for loss of apo B from LDL in human atherosclerotic lesions: extracellular cholesteryl ester lipid particles lacking apo B. Atherosclerosis 105, 227-234.
21. Leake, D.S. (1997). Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions? Atherosclerosis 129, 149-157.
22. Lecaille, F., Authie, E., Moreau, T., Serveau, C., Gauthier, F., and Lalmanach, G. (2001). Subsite specificity of trypanosomal cathepsin L-like cysteine proteases. Probing the S2 pocket with phenylalanine-derived amino acids. Eur. J. Biochem. 268, 2733-2741.
23. Lecaille, F., Kaleta, J., and Bromme, D. (2002). Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 102, 4459-4488.
24. Lecaille, F., Weidauer, E., Juliano, M.A., Bromme, D., and Lalmanach, G. (2003). Probing cathepsin K activity with a selective substrate spanning its active site. Biochem. J. 375, 307-312.
25. Linnevers, C.J., McGrath, M.E., Armstrong, R., Mistry, F.R., Barnes, M.G., Klaus, J.L., Palmer, J.T., Katz, B.A., and Bromme, D. (1997). Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex. Protein Sci. 6, 919-921.
26. Liu, J., Sukhova, G.K., Sun, J.S., Xu, W.H., Libby, P., and Shi, G.P. (2004). Lysosomal cysteine proteases in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 1359-1366.
27. Liu, J., Ma, L., Yang, J., Ren, A., Sun, Z., Yan, G., Sun, J., Fu, H., Xu, W., Hu, C., and Shi, G.P. (2005). Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 186, 411-419.
28. McEneny, J., Loughrey, C.M., McNamee, P.T., Trimble, E.R., and Young, I.S. (1997). Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 129, 215-220.
29. McEneny, J., McMaster, C., Trimble, E.R., and Young, I.S. (2002). Rapid isolation of VLDL subfractions: assessment of composition and susceptibility to copper-mediated oxidation. J. Lipid Res. 43, 824-831.
30. Naghavi, M., John, R., Naguib, S., Siadaty, M.S., Grasu, R., Kurian, K.C., van Winkle, W.B., Soller, B., Litovsky, S., Madjid, M., et al. (2002). pH heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis 164, 27-35.
31. Oorni, K., Pentikainen, M.O., Ala-Korpela, M., and Kovanen, P.T. (2000). Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J. Lipid Res. 41, 1703-1714.
32. Oorni, K., Sneck, M., Bromme, D., Pentikainen, M.O., Lindstedt, K.A., Mayranpaa, M., Aitio, H., and Kovanen, P.T. (2004). Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J. Biol. Chem. 279, 34776-34784.
33. Parks, W.C. (1999). Who are the proteolytic culprits in vascular disease? J. Clin. Invest. 104, 1167-1168.
34. Pauly, T.A., Sulea, T., Ammirati, M., Sivaraman, J., Danley, D.E., Griffor, M.C., Kamath, A.V., Wang, I.K., Laird, E.R., Seddon, A.P., et al. (2003). Specificity determinants of human cathepsin s revealed by crystal structures of complexes. Biochemistry 42, 3203-3213.
35. Pentikainen, M.O., Oorni, K., Ala-Korpela, M., and Kovanen, P.T. (2000). Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J. Intern. Med. 247, 359-370.
36. Pillay, C.S., Elliott, E., and Dennison, C. (2002). Endolysosomal proteolysis and its regulation. Biochem. J. 363, 417-429.
37. Puzer, L., Cotrin, S.S., Alves, M.F., Egborge, T., Araujo, M.S., Juliano, M.A., Juliano, L., Bromme, D., and Carmona, A.K. (2004). Comparative substrate specificity analysis of recombinant human cathepsin V and cathepsin L. Arch. Biochem. Biophys. 430, 274-283.
38. Reddy, V.Y., Zhang, Q.Y., and Weiss, S.J. (1995). Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA 92, 3849-3853.
39. Segrest, J.P., Jones, M.K., De Loof, H., and Dashti, N. (2001). Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42, 1346-1367.
40. Simionescu, N., Vasile, E., Lupu, F., Popescu, G., and Simionescu, M. (1986). Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am. J. Pathol. 123, 109-125.
41. Song, J., Xu, P., Xiang, H., Su, Z., Storer, A.C., and Ni, F. (2000). The active-site residue Cys-29 is responsible for the neutral-pH inactivation and the refolding barrier of human cathepsin B. FEBS Lett. 475, 157-162.
42. Sukhova, G.K., Shi, G.P., Simon, D.I., Chapman, H.A., and Libby, P. (1998). Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102, 576-583.
43. Sukhova, G.K., Zhang, Y., Pan, J.H., Wada, Y., Yamamoto, T., Naito, M., Kodama, T., Tsimikas, S., Witztum, J.L., Lu, M.L., et al. (2003). Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 111, 897-906.
44. Torzewski, M., Suriyaphol, P., Paprotka, K., Spath, L., Ochsenhirt, V., Schmitt, A., Han, S.R., Husmann, M., Gerl, V.B., Bhakdi, S., and Lackner, K.J. (2004). Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24, 2130-2136.
45. Vasile, E., Simionescu, M., and Simionescu, N. (1983). Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ. J. Cell. Biol. 96, 1677-1689.
46. Wang, B., Shi, G.P., Yao, P.M., Li, Z., Chapman, H.A., and Bromme, D. (1998). Human cathepsin F. Molecular cloning, functional expression, tissue localization, and enzymatic characterization. J. Biol. Chem. 273, 32000-32008.
47. Yang, C., Gu, Z.W., Yang, M., and Gotto, A.M. Jr. (1994). Primary structure of apoB-100. Chem. Phys. Lipids 67-68, 99-104.
48. Yasuda, Y., Li, Z., Greenbaum, D., Bogyo, M., Weber, E., and Bromme, D. (2004). Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J. Biol. Chem. 279, 36761-36770.
49. Zieske, A.W., Malcom, G.T., and Strong, J.P. (2002). Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr. Pathol. Mol. Med. 21, 213-237.